• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在烧伤重症监护病房暴发期间，对头孢地尔耐药鲍曼不动杆菌的进化和传播。

Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.

机构信息

Department of Pharmacy, Cooperman Barnabas Medical Center, Livingston, New Jersey, USA.

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

出版信息

Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.

DOI:10.1093/cid/ciac647
PMID:35974429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10169418/
Abstract

We report on 11 critically ill burn patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. Clinical success was achieved in 36% and complicated by treatment-emergent resistance and interpatient transmission of cefiderocol-resistant A. baumannii. Resistant isolates harbored disrupted pirA and piuA genes that were not disrupted among susceptible isolates.

摘要

我们报告了 11 例重症烧伤患者使用头孢地尔治疗碳青霉烯类耐药鲍曼不动杆菌感染的情况。临床治愈率为 36%，但治疗中出现了耐药性和耐头孢地尔的鲍曼不动杆菌在患者间的传播。耐药分离株携带的 pirA 和 piuA 基因被破坏，而敏感分离株则没有被破坏。

相似文献

1
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.在烧伤重症监护病房暴发期间，对头孢地尔耐药鲍曼不动杆菌的进化和传播。
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
2
Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.在烧伤重症监护病房发生碳青霉烯类耐药鲍曼不动杆菌爆发期间，氨苄西林-舒巴坦/头孢他啶-阿维巴坦联合治疗的演变、控制和成功。
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1453-1459. doi: 10.1007/s10096-024-04840-9. Epub 2024 Apr 27.
3
Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .碳青霉烯类耐药 中治疗期出现的头孢他啶耐药与铁载体受体中的插入序列 IS 有关。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.
4
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.分析 ICU 患者下呼吸道感染的鲍曼不动杆菌分离株的表型和分子特征。
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
5
Accumulation of Antibiotic Resistance Genes in Carbapenem-Resistant Isolates Belonging to Lineage 2, Global Clone 1, from Outbreaks in 2012-2013 at a Tehran Burns Hospital.2012-2013 年德黑兰烧伤医院暴发疫情中属于 2 谱系全球克隆 1 型的碳青霉烯类耐药分离株中抗生素耐药基因的积累。
mSphere. 2020 Apr 8;5(2):e00164-20. doi: 10.1128/mSphere.00164-20.
6
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.耐碳青霉烯类肠杆菌科细菌（CRAB）在医院环境中的适应性导致持续暴发。
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
7
First detection of a cefiderocol-resistant and extensively drug-resistant Acinetobacter baumannii clinical isolate in Bulgaria.保加利亚首次检出对头孢地尔耐药且广泛耐药的鲍曼不动杆菌临床分离株。
Acta Microbiol Immunol Hung. 2024 Jan 23;71(1):25-36. doi: 10.1556/030.2024.02201. Print 2024 Mar 26.
8
Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.从美国加利福尼亚州洛杉矶县两次医院感染暴发中分离出的鲍曼不动杆菌菌株的分子特征及药敏性
BMC Infect Dis. 2016 May 4;16:194. doi: 10.1186/s12879-016-1526-y.
9
Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing Carried on a Plasmid.医院内携带质粒的广泛耐药鲍曼不动杆菌的暴发
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00797-17. Print 2017 Nov.
10
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.碳青霉烯类耐药 株中阿维巴坦和舒巴坦与头孢地尔的异性拮抗作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.

引用本文的文献

1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.评价头孢地尔的抗菌药物敏感性试验方法：对当前实践和未来方向的综述与专家意见
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
treatment strategies: a review of therapeutic challenges and considerations.治疗策略：治疗挑战与考量综述
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
3
Comparative activity of sulbactam with avibactam or durlobactam against carbapenem-resistant .舒巴坦与阿维巴坦或杜洛巴坦对耐碳青霉烯类细菌的比较活性。
JAC Antimicrob Resist. 2025 Jun 23;7(3):dlaf098. doi: 10.1093/jacamr/dlaf098. eCollection 2025 Jun.
4
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
5
Heterogeneity and Genomic Plasticity of Acinetobacter baumannii and Acinetobacter nosocomialis Isolates Recovered from Clinical Samples in India.从印度临床样本中分离出的鲍曼不动杆菌和医院不动杆菌的异质性和基因组可塑性。
Curr Microbiol. 2024 Oct 19;81(12):415. doi: 10.1007/s00284-024-03942-z.
6
Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.微生物组衍生的抗菌肽对重要的优先病原体鲍曼不动杆菌具有治疗活性。
NPJ Biofilms Microbiomes. 2024 Sep 30;10(1):92. doi: 10.1038/s41522-024-00560-2.
7
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant infections.接受头孢地尔治疗碳青霉烯耐药感染患者中头孢地尔异质性耐药的发生率。
JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct.
8
Challenges Facing Two Outbreaks of Carbapenem-Resistant : From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants.耐碳青霉烯类药物的两次暴发所面临的挑战：从头孢地尔敏感性试验到头孢地尔耐药突变体的出现
Antibiotics (Basel). 2024 Aug 21;13(8):784. doi: 10.3390/antibiotics13080784.
9
transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- drug development and AMR preparedness.表达对美罗培南耐药的耐酶青霉素酶和金属β-内酰胺酶的转化子：用于药物开发和抗微生物药物耐药性准备的新工具。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0022224. doi: 10.1128/aac.00222-24. Epub 2024 Aug 27.
10
Unveiling the Secrets of : Resistance, Current Treatments, and Future Innovations.揭示 ：耐药性、当前治疗方法和未来创新的秘密。
Int J Mol Sci. 2024 Jun 21;25(13):6814. doi: 10.3390/ijms25136814.

本文引用的文献

1
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.美国医院中的耐碳青霉烯类鲍曼不动杆菌：流行谱系的多样化与抗菌药物耐药性
mBio. 2022 Apr 26;13(2):e0275921. doi: 10.1128/mbio.02759-21. Epub 2022 Mar 21.
2
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.美国传染病学会关于治疗产 AmpC β-内酰胺酶肠杆菌科、耐碳青霉烯类鲍曼不动杆菌和嗜麦芽窄食单胞菌感染的指南。
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
3
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists.鲍曼不动杆菌感染治疗的当代观点：来自传染病药师协会的见解
Infect Dis Ther. 2021 Dec;10(4):2177-2202. doi: 10.1007/s40121-021-00541-4. Epub 2021 Oct 14.
4
Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020.2020年2月至7月新泽西州一家急症医院在新冠病毒疾病住院人数激增期间医院获得性耐碳青霉烯鲍曼不动杆菌感染和定植增加情况
MMWR Morb Mortal Wkly Rep. 2020 Dec 4;69(48):1827-1831. doi: 10.15585/mmwr.mm6948e1.
5
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
6
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.头孢地尔在 ICU 患者治疗鲍曼不动杆菌和其他碳青霉烯类耐药革兰氏阴性菌感染中的应用。
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
7
Microbiome in the setting of burn patients: implications for infections and clinical outcomes.烧伤患者的微生物组：对感染和临床结局的影响。
Burns Trauma. 2020 Aug 14;8:tkaa033. doi: 10.1093/burnst/tkaa033. eCollection 2020.
8
CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database.CARD 2020：利用综合抗生素耐药数据库进行抗生素耐药组监测。
Nucleic Acids Res. 2020 Jan 8;48(D1):D517-D525. doi: 10.1093/nar/gkz935.
9
Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications.开放获取的细菌群体基因组学：BIGSdb软件、PubMLST.org网站及其应用。
Wellcome Open Res. 2018 Sep 24;3:124. doi: 10.12688/wellcomeopenres.14826.1. eCollection 2018.
10
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.多黏菌素单用与多黏菌素联合美罗培南治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染：一项开放标签、随机对照试验。
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.